{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:01:45Z","timestamp":1789542105145,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11096-023-01545-5","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T12:02:48Z","timestamp":1677499368000},"page":"659-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Developing supervised machine learning algorithms to evaluate the therapeutic effect and laboratory-related adverse events of cyclosporine and tacrolimus in renal transplants"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamik","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"issue":"5 Pt 2","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1600-6143.2006.01270.x","volume":"6","author":"HU Meier-Kriesche","year":"2006","unstructured":"Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994\u20132004. Am J Transplant. 2006;6(5 Pt 2):1111\u201331.","journal-title":"Am J Transplant"},{"issue":"7","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/jcm9072193","volume":"9","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Kovvuru K, et al. Impacts of high intra- and inter-individual variability in tacrolimus pharmacokinetics and fast tacrolimus metabolism on outcomes of solid organ transplant recipients. J Clin Med. 2020;9(7):2193.","journal-title":"J Clin Med"},{"issue":"6","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/ki.2013.484","volume":"85","author":"T van Gelder","year":"2014","unstructured":"van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int. 2014;85(6):1267\u20138.","journal-title":"Kidney Int"},{"issue":"2","key":"1545_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001102","volume":"7","author":"E Nobakht","year":"2021","unstructured":"Nobakht E, Jagadeesan M, Paul R, et al. Precision medicine in kidney transplantation: Just hype or a realistic hope? Transplant Direct. 2021;7(2): e650.","journal-title":"Transplant Direct"},{"issue":"2","key":"1545_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/pharmaceutics14020261","volume":"14","author":"DH Lee","year":"2022","unstructured":"Lee DH, Lee H, Yoon HY, et al. Association of P450 oxidoreductase gene polymorphism with tacrolimus pharmacokinetics in renal transplant recipients: a systematic review and meta-analysis. Pharmaceutics. 2022;14(2):261.","journal-title":"Pharmaceutics"},{"issue":"7","key":"1545_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5500\/wjt.v11.i7.277","volume":"11","author":"N Seyahi","year":"2021","unstructured":"Seyahi N, Ozcan SG. Artificial intelligence and kidney transplantation. World J Transplant. 2021;11(7):277\u201389.","journal-title":"World J Transplant"},{"key":"1545_CR7","doi-asserted-by":"publisher","first-page":"46936","DOI":"10.1038\/srep46936","volume":"8","author":"J Tang","year":"2018","unstructured":"Tang J, Liu R, Zhang YL, et al. Application of machine-learning models to predict tacrolimus stable dose in renal transplant recipients. Sci Rep. 2018;8:46936.","journal-title":"Sci Rep"},{"issue":"7","key":"1545_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.3390\/ijms21072517","volume":"21","author":"JA Gim","year":"2020","unstructured":"Gim JA, Kwon Y, Lee HA, et al. A machine learning-based identification of genes affecting the pharmacokinetics of tacrolimus using the DMETTM plus platform. Int J Mol Sci. 2020;21(7):2517.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1545_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191921","volume":"13","author":"K Thishya","year":"2018","unstructured":"Thishya K, Vattam KK, Naushad SM, et al. Artificial neural network model for predicting the bioavailability of tacrolimus in patients with renal transplantation. PLoS ONE. 2018;13(4):e0191921.","journal-title":"PLoS ONE"},{"key":"1545_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00439-021-02385-x","volume":"141","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Lauschke VM. Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health. Hum Genet. 2021;141:1113\u201336.\u00a0https:\/\/doi.org\/10.1007\/s00439-021-02385-x.","journal-title":"Hum Genet"},{"issue":"5","key":"1545_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/jpm12050823","volume":"12","author":"K Sridharan","year":"2022","unstructured":"Sridharan K, Shah S, Jassim A, et al. Evaluation of pharmacogenetics of drug-metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants. J Pers Med. 2022;12(5):823.","journal-title":"J Pers Med."},{"issue":"2","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jclinepi.2014.11.010","volume":"68","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. J Clin Epidemiol. 2015;68(2):134\u201343.","journal-title":"J Clin Epidemiol"},{"key":"1545_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.711943","volume":"12","author":"TAM Mulder","year":"2021","unstructured":"Mulder TAM, van Eerden RAG, de With M, et al. CYP3A4\u221722 genotyping in clinical practice: Ready for implementation? Front Genet. 2021;12: 711943.","journal-title":"Front Genet"},{"issue":"4","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines8040094","volume":"8","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Almenara S, Navares-G\u00f3mez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8(4):94.","journal-title":"Biomedicines"},{"issue":"1","key":"1545_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40360-018-0202-9","volume":"19","author":"M Li","year":"2018","unstructured":"Li M, Xu M, Liu W, et al. Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome. BMC Pharmacol Toxicol. 2018;19(1):14.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"11","key":"1545_CR16","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3390\/pharmaceutics14112441","volume":"14","author":"A Chernov","year":"2022","unstructured":"Chernov A, Kilina D, Smirnova T, et al. Pharmacogenetic study of the impact of ABCB1 single nucleotide polymorphisms on the response to cyclosporine in psoriasis patients. Pharmaceutics. 2022;14(11):2441.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1545_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.bbrc.2005.09.165","volume":"338","author":"BS Masters","year":"2005","unstructured":"Masters BS. The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases. Biochem Biophys Res Commun. 2005;338(1):507\u201319.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1545_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1073\/pnas.0711621105","volume":"105","author":"N Huang","year":"2008","unstructured":"Huang N, Agrawal V, Giacomini KM, et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA. 2008;105(5):1733\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1545_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/FPC.0b013e32835dc113","volume":"23","author":"L Elens","year":"2013","unstructured":"Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet Genomics. 2013;23(3):148\u201355.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"1545_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/17425255.2016.1170808","volume":"12","author":"JT Tang","year":"2016","unstructured":"Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12(5):555\u201365.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1545_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/pgs.10.105","volume":"11","author":"P Wang","year":"2010","unstructured":"Wang P, Mao Y, Razo J, et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010;11(10):1389\u2013402.","journal-title":"Pharmacogenomics"},{"key":"1545_CR22","doi-asserted-by":"crossref","unstructured":"Wendler T, Grottrup S. Regression models. In: Data mining with SPSS modeler. Springer, Cham, Switzerland, pp 367\u2013546.","DOI":"10.1007\/978-3-030-54338-9_5"},{"issue":"4","key":"1545_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrg1578","volume":"6","author":"DJ Hunter","year":"2005","unstructured":"Hunter DJ. Gene-environment interactions in human diseases. Nat Rev Genet. 2005;6(4):287\u201398.","journal-title":"Nat Rev Genet"},{"issue":"9","key":"1545_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.5414\/CP202152","volume":"53","author":"JJ Zhang","year":"2015","unstructured":"Zhang JJ, Liu SB, Xue L, et al. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2015;53(9):728\u201336.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"1545_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/00498254.2012.752118","volume":"43","author":"SD Chitnis","year":"2013","unstructured":"Chitnis SD, Ogasawara K, Schniedewind B, et al. Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism. Xenobiotica. 2013;43(7):641\u20139.","journal-title":"Xenobiotica"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01545-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T11:15:43Z","timestamp":1686222943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01545-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01545-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}